RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
1–2 drops in each affected eye |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
1–2 drops up to 4 times daily |
|
Maximum dose
|
4 applications per day |
|
Maximum duration
|
3–5 days (short-term use only) |
| Parameter | Recommendation |
|
Starting dose
|
1–2 drops per nostril |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
1–2 drops per nostril up to 4 times daily |
|
Maximum dose
|
4 applications per day |
|
Maximum duration
|
Not more than 5 consecutive days |
| Parameter | Recommendation |
|
Starting dose
|
Few drops applied on cotton pledget to bleeding point |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
Single application during procedure |
|
Maximum dose
|
Single use per procedure |
|
Duration
|
Single-use during procedure only |
| Age Group | Dose | Frequency | Maximum Duration |
| ≥6 years | 1 drop in affected eye | Up to 4 times daily | 3 days |
| Age Group | Dose | Frequency | Maximum Duration |
| 2–6 years | 1 drop per nostril | 2–3 times daily | 3 days |
| >6 years | 1–2 drops per nostril | 2–3 times daily | 5 days |
| Severity | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | No dose adjustment required |
| Severe impairment | No dose adjustment required |
| Consideration | Recommendation |
| Overall safety | Limited human data; use only if clearly necessary |
| Risk | Potential systemic vasoconstriction with high doses or prolonged use |
| When it may be used | Short-term use if benefits outweigh risks; avoid prolonged use |
| Preferred alternatives | Preservative-free lubricant eye drops for conjunctival irritation; saline nasal drops for congestion |
| Monitoring | Maternal blood pressure if repeated dosing required |
| Consideration | Recommendation |
| Compatibility | Likely compatible with ophthalmic use due to minimal systemic absorption |
| Drug levels in milk | Expected to be low with proper topical use |
| Preferred alternatives | Saline nasal drops; preservative-free lubricant eye drops |
| Infant monitoring | Drowsiness, feeding difficulties if prolonged maternal use or high doses |
| Consideration | Recommendation |
| Starting dose | Lowest effective dose (1 drop) |
| Titration | Not applicable; use shortest duration possible |
| Risks | Increased sensitivity to systemic adrenergic effects (hypertension, tachycardia, CNS stimulation) |
| Monitoring | Blood pressure, cognition, especially with nasal route |
| Interacting Drug | Effect / Mechanism | Recommendation |
| Monoamine oxidase inhibitors (MAOIs) | Risk of hypertensive crisis due to potentiation of sympathomimetic effects |
Contraindicated — avoid within 14 days of MAOI use
|
| Tricyclic antidepressants (e.g., amitriptyline, imipramine) | Enhanced sympathomimetic effect; risk of hypertension, arrhythmias |
Avoid or monitor closely
|
| Other sympathomimetics (phenylephrine, pseudoephedrine) | Additive cardiovascular effects |
Avoid concurrent use
|
| Interacting Drug | Effect / Mechanism | Recommendation |
| Beta-blockers | May mask mutual effects on heart rate and blood pressure | Monitor blood pressure and heart rate |
| Antihypertensives | May reduce antihypertensive efficacy | Monitor blood pressure |
| CNS depressants | May potentiate sedative effects in children/infants if systemic absorption occurs | Avoid concurrent use in paediatric patients |
| Other topical ophthalmic/nasal adrenergics | Additive vasoconstriction | Avoid using multiple agents together |
| Adverse Effect | Clinical Note |
| Systemic absorption in children | Bradycardia, CNS depression, hypotonia, respiratory depression, coma — requires immediate discontinuation and supportive care |
| Acute angle-closure glaucoma | In predisposed patients (ophthalmic use); requires emergency ophthalmology referral |
| Hypertensive episodes | In susceptible individuals; discontinue immediately |
| Cardiac arrhythmias | With significant systemic absorption; more common in elderly or cardiovascular disease patients |
| Phase | Parameters |
|
Baseline
|
Assess for predisposing conditions (glaucoma, cardiovascular disease, hypertension) |
|
During use (≥3 days)
|
Monitor for rebound congestion or hyperaemia |
|
Children
|
Monitor for sedation, drowsiness, lethargy, irritability, hypotonia |
|
Long-term
|
Not recommended; monitor and reassess if use exceeds 5 days |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.